Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
RESEARCH TOOLSreports
Holding ALXO?
Track your performance easily
ALXO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.19 - $17.83
Previous Close$1.83
Volume545.91K
Average Volume (3M)955.54K
Market Cap
$96.52M
Enterprise Value-$42.22M
Total Cash (Recent Filing)$148.57M
Total Debt (Recent Filing)$9.84M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 06, 2025EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding52,743,104
10 Day Avg. Volume1,749,747
30 Day Avg. Volume955,544
Standard Deviation0.30
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$10.00Price Target Upside446.45% Upside
Rating ConsensusHold
Number of Analyst Covering4
ALX Oncology Holdings News
PremiumCompany Announcements
ALX Oncology Strengthens Leadership with Key Appointment
PremiumCompany Announcements
ALX Oncology Highlights Promising Trial Results
PremiumCompany Announcements
ALX Oncology Reports Clinical Progress and Financial StabilityBulls Say, Bears Say
Bulls Say
Clinical DataPositive clinical data update strengthens solid tumor thesis for Evorpacept.
Combination TherapyThe combination therapy of evorpacept and zanidatamab was well-tolerated, with a low percentage of patients experiencing serious adverse effects.
Research And DevelopmentALX Oncology remains on track to report multiple clinical updates from several studies in 2025, demonstrating a robust pipeline and ongoing commitment to research and development.
Bears Say
Clinical TrialsFull Phase II data in gastric failed to meet expectations and the efficacy had come way down in H2 of the study post interim.
Financial PerformanceThe company reported no revenues and a net loss of $0.58 per share, which is better than the consensus estimated net loss of $0.78 per share.
Investor SentimentShort interest is relatively high, indicating some skepticism among investors regarding the company's prospects.
---
Ownership Overview
3.50% Insiders
17.99% Mutual Funds
48.27% Other Institutional Investors
23.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $1.19 and its highest was $17.82 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
Currently, no data Available
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Mar 06, 2025 which is in 70 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Nov 07, 2024. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.78 by $0.2.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -$0.67.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 52,743,103 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.78. Following the earnings report the stock price went down -3.974%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Among the largest hedge funds holding ALX Oncology Holdings’s share is Graham Capital Management, L.P.. It holds ALX Oncology Holdings’s shares valued at 176K.
---
ALX Oncology Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (446.45% Upside)
$10.00 (446.45% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 72.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.10%
12-Months-Change
Fundamentals
Return on Equity
-98.94%
Trailing 12-Months
Asset Growth
-15.63%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
---
ALXO Stock 12 Month Forecast
Average Price Target
$10.00
▲(446.45% Upside)
Technical Analysis
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-16.69%
reiterated a buy rating 9 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -16.69% per trade.
---